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Tumor suppressor p53 plays an important role in mediating growth
inhibition upon telomere dysfunction. Here, we show that loss of
the p53 target gene cyclin-dependent kinase inhibitor 1A (CDKN1A,
also known as p21WAF1/CIP1) increases apoptosis induction following
telomerase inhibition in a variety of cancer cell lines and mouse
xenografts. This effect is highly specific to p21, as loss of other
checkpoint proteins and CDK inhibitors did not affect apoptosis. In
telomerase, inhibited cell loss of p21 leads to E2F1- and p53-medi-
ated transcriptional activation of p53-upregulated modulator of
apoptosis, resulting in increased apoptosis. Combined genetic or
pharmacological inhibition of telomerase and p21 synergistically
suppresses tumor growth. Furthermore, we demonstrate that simul-
taneous inhibition of telomerase and p21 also suppresses growth of
tumors containing mutant p53 following pharmacological restora-
tion of p53 activity. Collectively, our results establish that inacti-
vation of p21 leads to increased apoptosis upon telomerase
inhibition and thus identify a genetic vulnerability that can be
exploited to treat many human cancers containing either wild-type
or mutant p53.
Aprominent feature that distinguishes cancer cells from theirnormal counterparts is the expression of telomerase. Telo-
merase is a specialized ribonucleoprotein reverse transcriptase
that synthesizes the telomeric DNA ends to maintain telomere
length (1). During early tumorigenesis, telomerase expression is
necessary to bypass replicative senescence, enabling immortali-
zation of human cells (2). Notably, telomerase also represents an
attractive target for cancer therapy because a large majority of
cancer cells depend on telomerase expression for survival. Ac-
cordingly, genetic or pharmacological inhibition of telomerase
has been shown to suppress growth of cancer cells (3). In fact,
the telomerase inhibitor imetelstat, an oligonucleotide that in-
hibits telomerase activity by binding to the RNA component of
human telomerase RNA (hTR), has advanced to the clinic for
treatment of various hematological malignancies and solid
tumors. To date, however, telomerase-based monotherapies
have not been successful, underscoring the need to understand
in greater detail how cancer cells respond to telomerase inhibition.
Previous studies have shown that the tumor suppressor p53
pathway plays a central role in regulating the cellular response to
telomerase inhibition and telomere shortening (4). Genetic de-
letion of p53 in mice or RNA interference (RNAi)-mediated
inhibition of p53 counteracts the growth suppression that occurs
following telomerase inhibition. Furthermore, p53 loss cooper-
ates with telomerase dysfunction to promote tumorigenesis (4).
CDKN1A (also known as p21WAF1/CIP1) is a cyclin-dependent ki-
nase inhibitor and a direct transcriptional target of p53 (5, 6). p21
mediates several important physiological effects of p53, includ-
ing DNA-damage–induced cell cycle checkpoints (7, 8). In ad-
dition to its role in cell cycle regulation, p21 has been shown in
a variety of studies to repress apoptosis (9–13).
Here, we study the role of p21 in the context of telomerase in-
hibition. We find that abrogation of p21 function induces apoptosis
in cancer cells following telomerase inhibition through up-regula-
tion of p53-upregulated modulator of apoptosis (PUMA), a proa-
poptotic protein. Based upon these results, we go on to show that
simultaneous genetic or pharmacological inhibition of telomerase
and p21 can synergistically suppress tumor growth, even in p53
pathway-defective cancers.
Results
Induction of Apoptosis Following Telomerase Inhibition in Cancer Cells
Lacking p21. As described above, p53 is known to play an impor-
tant role in the cellular response to telomere dysfunction, and
p21 is a major target of p53. However, the specific role of p21 in
human cancer cells with dysfunctional telomeres has not been
examined. Therefore, we asked whether cancer cells respond
differently to telomerase inhibition and consequential telomere
shortening in the presence or absence of p21. Toward this end, we
treated HCT116 cells and HCT116 p21 knockout cells (HCT116
p21KO) with the telomerase inhibitor imetelstat (14). We found
that imetelstat inhibited proliferation of HCT116 p21KO cells
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much more strongly than that of HCT116 cells (Fig. 1 A and B).
Notably, telomerase inhibition in HCT116 and HCT116 p21KO
cells was comparable (Fig. 1C). Additional experiments revealed
that growth inhibition of HCT116 p21KO cells was largely due to
increased apoptosis (Fig. 1 D–F). Furthermore, we knocked down
telomerase using two different short hairpin RNAs (shRNAs) in
HCT116 and HCT116 p21KO cells. Similar to the results with
imetelstat, we found that shRNA-mediated knockdown of telo-
merase inhibited proliferation of HCT116 p21KO cells more ef-
ficiently than that of HCT116 cells (SI Appendix, Fig. S1).
Guided by these cell culture results, we injected HCT116 or
HCT116 p21KO cells s.c. into athymic nude mice and monitored
tumor growth after treatment with imetelstat or a control mis-
match oligonucleotide. Similar to the cell culture results, we found
that imetelstat inhibited growth of HCT116 p21KO tumors more
effectively than that of HCT116 tumors (4.0-fold inhibition for
HCT116 p21KO versus 1.6-fold inhibition for HCT116 cells)
(Fig. 1G).
To determine the generality of these results, we used RNAi
to knock down p21 in HCT116 cells and the unrelated ACHN
(renal) and RKO (colorectal) human cancer cell lines (SI Ap-
pendix, Figs. S2 and S3). Cells transduced with p21 shRNAs or
a nonspecific control shRNA were treated with imetelstat or a
mismatch oligonucleotide and monitored for proliferation. As
observed in HCT116 p21KO cells, shRNA-mediated knockdown
of p21 enhanced growth inhibition by imetelstat in HCT116,
ACHN, and RKO cells by inducing apoptosis (SI Appendix, Fig.
S2 and Fig. 2 A–J). In complete agreement with our cell culture
experiments, we observed that treatment with imetelstat inhibited
the growth of p21 shRNA expressing ACHN and RKO tumors
in mice much more strongly than ACHN and RKO tumors ex-
pressing a nonspecific control shRNA (Fig. 2 K and L).
We also analyzed the imetelstat sensitivity of four additional
human cancer cell lines—LOX IMVI (melanoma), UACC62
(melanoma), CAKI (clear cell carcinoma), and NCI H460 (lung
adenocarcinoma)—that express either high or low levels of p21.
Similar to the results presented above, cell lines expressing a low
level of p21 (NCI H460) were sensitive to imetelstat-mediated
growth inhibition, whereas cell lines expressing a high level of
p21 (LOX IMVI, UACC62, and CAKI) were not (SI Appendix,
Fig. S3). In fact, proliferation of imetelstat-treated LOX IMVI
and UACC62 cells was higher than that of the mismatch oligo-
nucleotide-treated cells (SI Appendix, Fig. S3), possibly due to
the activation of Alternative Lengthening of Telomeres (ALT)
pathway (SI Appendix, Fig. S3). Taken together, these results
indicate that loss of p21 sensitizes diverse cancer cell lines to
tumor inhibition and apoptosis following abrogation of telo-
merase activity.
Role of Other Checkpoint Proteins and Other CDK Inhibitors in
Telomerase Inhibition-Induced Apoptosis. p53 is necessary for
DNA-damage–mediated transcriptional activation of p21 (15),
and genetic deletion of p21 abrogates p53-mediated G1 and G2/M
checkpoints (8, 16). We therefore asked whether knockdown of
other checkpoint proteins also sensitizes cancer cells to telome-
rase inhibition-mediated apoptosis. Toward this end, we ana-
lyzed two previously described checkpoint proteins, mediator of
DNA damage checkpoint protein 1 (MDC1) and Nijmegen
breakage syndrome 1 (NBS1) (17–19). Notably, MDC1 has been
shown to have a role in detection and repair of human and
mouse telomeres that are rendered dysfunctional through in-
hibition of TRF2 (20), whereas MRE11–RAD50–NBS1 has been
shown to associate with TRF2 and human telomeres (21).
To test the effect of these proteins, MDC1 and NBS1 were
knocked down in HCT116 cells, followed by treatment with ime-
telstat. As a control, HCT116 cells expressing a nonspecific shRNA
were analyzed in parallel. In contrast to the results with p21, de-
pletion of NBS1 or MDC1 did not increase the sensitivity of
HCT116 cells to imetelstat-mediated growth suppression (SI
Appendix, Fig. S4).
Additionally, we also tested the role of a second cyclin-dependent
kinase inhibitor CDKN1B (also known as p27). In contrast to p21
loss, knockdown of p27 did not sensitize HCT116 cells to imetelstat-
induced apoptosis (SI Appendix, Fig. S5). Furthermore, although
the cancer cell lines used in our studies lacked CDKN2A (also
known as p16) (SI Appendix, Table S1) (22, 23), they varied in
their response to imetelstat. These results indicate that p16 ex-
pression also does not determine the response of cancer cells to
telomerase inhibition. Collectively, these results show that unlike
p21, loss of other checkpoint proteins (e.g., MDC1 and NBS1) or
other CDK inhibitors (e.g., p27 and p16) does not cooperate with
imetelstat to induce apoptosis.
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Fig. 1. Telomerase inhibition induces apoptosis in the absence of p21. Indicated cell lines were treated with mismatch oligonucleotide or imetelstat for 6 wk.
(A) Crystal violet staining of HCT116 wild-type and p21KO colonies. Representative wells are shown. (B) Relative cell viability was monitored by trypan blue
exclusion assay. (C) Telomerase activities of HCT116 wild-type and HCT116 p21KO cells. (D) Flow cytometry analysis to monitor apoptotic cells. (E) Cleaved
caspase 3 immunoblot to measure apoptosis. Actin was used as a loading control. (F) % Annexin V–FITC–positive cells under indicated treatment conditions.
(G) Average tumor volumes for indicated cell lines are presented at indicated conditions. ***P < 0.0001.
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We also tested whether a general cellular stress could cooperate
with either imetelstat treatment or p21 loss to induce apoptosis.
Our results show that tunicamycin, which induces ER stress, had
no cooperative effect with either imetelstat treatment or p21 loss
on cell proliferation or apoptosis (SI Appendix, Fig. S6).
Apoptosis Induction After Telomerase Inhibition in Cancer Cells
Lacking p21 Does Not Involve Telomere Attrition or ALT. We next
sought to understand the mechanism by which apoptosis is in-
duced by imetelstat in HCT116 p21KO cells. First, we examined
whether loss of p21 affects the ability of imetelstat to induce
telomere shortening. SI Appendix, Fig. S7 A–D shows that there
was no significant difference between imetelstat-treated HCT116
and HCT116 p21KO cells in either the extent of telomere short-
ening or the number of signal-free chromosomal ends. Although
in most cancer cells maintenance of telomere length depends on
telomerase activity, in about 10–15% of cancers telomere length is
maintained through an alternative ALT pathway (24). The mech-
anism of ALT has not been fully elucidated, however a general
consensus is that it requires homologous recombination (24).
Furthermore, previous studies have shown that, following telo-
merase inhibition, cancer cells can survive by activating the ALT
pathway (24, 25). We therefore tested whether the ALT pathway
was more active in HCT116 cells than HCT116 p21KO cells after
imetelstat treatment by monitoring partially single-stranded telo-
meric (CCCTAA)n DNA circles (C-circles), a characteristic, quan-
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Fig. 2. shRNA-mediated p21 knockdown in unrelated human cancer cell lines sensitizes them to telomerase inhibition-mediated apoptosis. Analysis of RKO
(A–E) and ACHN (F–J) cells stably transduced with nonspecific control (NS) or two different p21 shRNAs. (A–E and F–J) Cells were treated with mismatch
oligonucleotide or with imetelstat for 6 wk. (A and F) Colony formation monitored by crystal violet staining. (B and G) Cell viability was measured by trypan
blue exclusion assay. Cell viability relative to mismatch oligonucleotide is plotted. (C and H) Telomerase activity as measured by the TRAP assay and plotted
relative to the mismatch oligonucleotide. (D and I) Cleaved caspase 3 immunoblot to measure apoptosis. Actin was used as a loading control. (E and J) %
Annexin V–FITC–positive cells under indicated treatment conditions. (K and L) Average tumor volumes for indicated cell lines for indicated conditions are
shown. **P < 0.001; ***P < 0.0001.
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tifiable marker of ALT activity (26). As expected, the previously
described ALT-positive osteosarcoma cell line U2OS produced
C-circles, whereas ALT-negative HeLa cells did not (SI Appendix,
Fig. S7E). Notably, we did not detect C-circles in either HCT116
or HCT116 p21KO cells, before or after imetelstat treatment,
indicating that ALT activity does not explain the differential re-
sponse to imetelstat. As an additional control, we analyzed the
effect of telomerase inhibition in cancer cell line U2OS, in which
the ALT pathway is active, and thus these cells do not depend
upon telomerase expression for survival (27). As expected, treat-
ment with imetelstat did not affect the proliferation of U2OS cells
in the absence or presence of p21 shRNAs (SI Appendix, Fig. S8).
Collectively, these results further confirm that imetelstat inhibits
telomerase activity to prevent growth of cancer cells that are de-
pendent upon telomerase activity for survival.
P53- and E2F1-Mediated PUMA Activation in Cells Lacking p21 After
Telomerase Inhibition. In addition to promoting cell cycle arrest in
response to DNA damage, the tumor suppressor p53 activates
proapoptotic genes such as BAX, BAK, and PUMA to induce
apoptosis (28–32). We therefore monitored expression of BAX,
BAK, and PUMA in HCT116 and HCT116 p21KO cells treated
with imetelstat. Unexpectedly, imetelstat treatment induced PUMA
expression to substantially higher levels in HCT116 p21KO cells
compared with HCT116 cells (Fig. 3 A and B). Likewise, shRNA-
mediated knockdown of p21 in RKO and ACHN cells led to a large
increase in PUMA expression following imetelstat treatment (SI
Appendix, Fig. S9 A and B as well as G and H). By contrast, fol-
lowing imetelstat treatment, BAK expression was actually higher in
HCT116 cells than in HCT116 p21KO cells, and BAX expression
was comparable in the two cell lines (Fig. 3 A and B).
Previous studies have shown that the E2F1 transcription factor
is an activator of PUMA transcription and that p21 can negatively
regulate E2F1 activity (33, 34). These two findings suggested that
E2F1 might activate PUMA expression in HCT116 p21KO cells
following imetelstat treatment. Consistent with this idea, fol-
lowing knockdown of E2F1 in HCT116 p21KO cells, imetelstat
treatment no longer activated PUMA expression (Fig. 3 C and D).
Furthermore, following shRNA-mediated knockdown of E2F1 in
HCT116 p21KO cells, imetelstat failed to inhibit cellular prolif-
eration (Fig. 3E and SI Appendix, Fig. S10) or efficiently induce
apoptosis (Fig. 3 F and G). Likewise, PUMA transcription was not
activated by imetelstat in HCT116 p53KO cells following p21
knockdown (Fig. 3 H and I). PUMA expression was comparable in
imetelstat-treated cells containing or depleted of the checkpoint
proteins NBS1 and MDC1 (SI Appendix, Fig. S4 F and L) as well
as in cells depleted of the CDK inhibitor p27 (SI Appendix, Fig.
S5F), again confirming the specific role of p21 in regulating ap-
optosis following telomerase inhibition. Thus, in the absence of
p21, E2F1 and p53 activate PUMA expression in telomerase-
inhibited cells.
Previous work has shown that p53 deficiency prevents the
growth inhibitory effects of telomere dysfunction (35). Indeed,
we found that HCT116 p53KO cells were more resistant to
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imetelstat than parental HCT116 cells (Fig. 3J and SI Appendix,
Fig. S10). These results led us to hypothesize that p53- and
E2F1-dependent activation of PUMA transcription is necessary
for apoptosis induction following telomerase inhibition in p21KO
cells. To test this idea, we used an HCT116 cell line bearing ho-
mozygous deletions in both p21 and PUMA (HCT116 p21/PUMA
DKO). Notably, loss of PUMA prevented growth inhibition and
apoptosis following treatment of HCT116 p21KO cells with
imetelstat (Fig. 4 A–C). Likewise, simultaneous shRNA-mediated
knockdown of PUMA (SI Appendix, Fig. S9 C and I) counteracted
imetelstat-mediated growth inhibition in RKO and ACHN cells
expressing a p21 shRNA (SI Appendix, Fig. S9 D–F and J–L).
To test whether loss of PUMA also rescued imetelstat-medi-
ated growth inhibition in vivo, we injected HCT116, HCT116
p21KO, and HCT116 p21/PUMA DKO cells into the flanks of
nude mice followed by treatment with either imetelstat or a
mismatch oligonucleotide. Consistent with the cell culture results,
imetelstat did not suppress growth of tumors lacking both p21 and
PUMA (Fig. 4D). Analysis of tumors by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL) showed
that after imetelstat treatment, apoptosis was significantly higher
in p21KO tumors compared with HCT116 p21/PUMA DKO
tumors (Fig. 4 E and F). Collectively, these results demonstrate
that in the absence of p21, telomerase inhibition leads to E2F1-
and p53-dependent transcriptional activation of PUMA, resulting
in apoptosis.
To establish the generality of the PUMA transcriptional acti-
vation mechanism, we analyzed five human cancer cell lines with
differing levels of p21 expression. We found that in a cell line
with low p21 levels (NCI H460) transcriptional activation of
PUMA after imetelstat treatment was substantially higher than
that of cell lines with high p21 levels (LOX IMVI, UACC62, and
CAKI; SI Appendix, Fig. S11A). Furthermore, knockdown of
PUMA (SI Appendix, Fig. S11B) rescued NCI H460 cells from
imetelstat-mediated growth inhibition (SI Appendix, Fig. S11 C
and D). Collectively, these results show that activation of PUMA
is necessary for apoptosis induction in cells lacking p21 after
telomerase inhibition.
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Synergistic Tumor Suppression by RNAi-Mediated p21 Depletion and
Imetelstat Treatment. The results described above suggested that
simultaneous inhibition of p21 and telomerase could synergisti-
cally suppress tumor growth. We therefore carried out a series of
experiments in which p21 function was abrogated using different
approaches and telomerase was inhibited with imetelstat. In the
first approach, we used a polymer nanoparticle-based system to
deliver a p21 small interfering RNA (siRNA) (36, 37). These
poly(lactic-co-glycolic acid) (PLGA) nanoparticles were coated
with the PEGylated cell-penetrating peptide, N terminus of
the CPP penetratin (ANTP), and loaded with a p21 siRNA. As
a control, a nonspecific negative control siRNA was similarly
encapsulated into modified PLGA nanoparticles. We then s.c.
injected HCT116 and ACHN cells into athymic nude mice and
systemically treated the mice with imetelstat and nanoparticles
encapsulated in siRNA. In good agreement with our cell cul-
ture results, the combination of a p21 siRNA and imetelstat
resulted in significantly stronger tumor suppression compared
with imetelstat alone (SI Appendix, Fig. S12 A and B and Table
S2). Furthermore, as expected, analyses of tumor lysates revealed
reduced p21 expression in p21 siRNA nanoparticle-injected
tumors (SI Appendix, Fig. S12 C and D), increased apoptosis
upon simultaneous inhibition of p21 and telomerase (SI Appendix,
Fig. S12 C and D), and reduced telomerase activity in imetelstat-
treated tumor samples (SI Appendix, Fig. S12 E and F).
Synergistic Tumor Suppression by Pharmacological Inhibition of
Telomerase and p21. The p21 siRNA results described above
provide proof-of-principle that systemic in vivo targeting of p21
can substantially enhance tumor suppression when combined with
telomerase inhibition. We next performed experiments in which
p21 function was abrogated by pharmacological inhibition in con-
junction with imetelstat treatment. We first inhibited p21 expres-
sion in HCT116 cells using sorafenib (Fig. 5A), which promotes
proteasome-mediated degradation of p21 (38). As predicted, we
found that sorafenib sensitized cells to imetelstat-mediated growth
inhibition and apoptosis induction (Fig. 5 B–D). Notably, reintro-
duction of p21 in HCT116 cells treated with imetelstat and sor-
afenib substantially counteracted growth inhibition and apoptosis
induction (Fig. 5 E–H), confirming that sorafenib functions by
down-regulating p21 activity. Next, we tested the combined effect
of imetelstat and sorafenib in suppressing tumor growth in
mouse xenografts. We found that simultaneous treatment with
imetelstat and sorafenib was substantially more effective at sup-
pressing growth of HCT116 xenografts than either drug alone and
thus functions in a synergistic manner (Fig. 5I and SI Appendix,
Table S2).
Toxicity analyses revealed that there were no significant dif-
ferences in the body weight or alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (AP),
whole blood counts, and renal activity markers in mice that were
treated with imetelstat sorafenib, or both, in comparison with the
control group (SI Appendix, Fig. S13). Finally, to determine the
generality of these results, we analyzed the effect of combined
imetelstat and sorafenib treatment on xenografts formed from
five additional human cancer cell lines representing four differ-
ent tissue origins. Notably, in all cases, treatment with both ime-
telstat and sorafenib was substantially more effective at suppressing
tumor growth than either drug alone (SI Appendix, Fig. S14 and
Table S2).
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Sorafenib has been shown to have cellular targets other than p21,
including BRAF and VEGF (39). Therefore, we asked whether an
alternative pharmacological inhibitor that more selectively tar-
gets p21 expression can, like sorafenib, cooperate with imetelstat to
suppress tumor growth. Toward this end, we used a recently iden-
tified pharmacological p21 inhibitor, UC2288 (Fig. 6A), which
down-regulates p21 levels through transcriptional and post-
transcriptional mechanisms (40). Furthermore, unlike Sorafenib,
UC2288 does not inhibit RAF kinase or VEGF activities (40). In
agreement with previous studies, we observed that treatment of
cancer cells with UC2288 led to decreased p21 levels (Fig. 6B).
Furthermore, whereas UC2288 alone had only modest growth
inhibitory effects, combining UC2288 with imetelstat potently
inhibited cancer cell growth by inducing apoptosis (Fig. 6 C–E).
The ability of UC2288 to inhibit growth was largely dependent
upon its ability to down-regulate p21 expression, because ectopic
expression of p21 counteracted growth inhibition and apoptosis
induction in UC2288 and imetelstat-treated cancer cells (Fig. 6 F–
H). Finally, we tested whether UC2288 can inhibit tumor growth
in vivo. Toward this end, we injected HCT116 and ACHN cells
BA
p21
Actin
Days 
7  14  21  28  
Vehicle
UC2288
Imetelstat
UC2288 
+ Imetelstat
I
Tu
m
or
 v
ol
um
e 
(m
m
3 )
C
el
l v
ia
bi
lit
y 
(%
)
UC2288 + +- -
UC2288 (µM)-       1.0      2.5     5.0
D E
F
Vehicle
UC2288
Imetelstat
UC2288 
+ Imetelstat
J
Tu
m
or
 v
ol
um
e 
(m
m
3 )
HCT116 ACHN
Cl
F3C N
H
o
o
N
H
N
CF3
UC2288
C
G
Cleaved Caspase 3
Actin
UC2288-         -         +        +
0
20
40
60
80
100
0
10
20
30
40
50
60
UC2288 + +- -
%
 A
nn
ex
in
 V
 p
os
iti
ve
 c
el
ls
 
C
el
l v
ia
bi
lit
y 
(%
)
Vector p21
UC2288
2.5 µM
0 µM
1 µM
0
20
40
60
80
100
0
10
20
30
40
50
60
%
 A
nn
ex
in
 V
 p
os
iti
ve
 c
el
ls
 
H
Cleaved Caspase 3
Actin
Vector p21
0
100
200
300
400
500
600
700
800
Days 
7  14  21  28  
Vector p21
0
100
200
300
400
500
600
700
800
UC2288 (µM)0     1     2.5 0     1     2.5
Imetelstat -         +         -        +* *** ***
**
******
***
*
*
*
***
ImetelstatMismatch ImetelstatMismatch
K L
p21
Cleaved Caspase 3
Actin
UC
22
88
Ve
hic
le
HCT116 ACHN
UC
22
88
+Im
ete
lst
at
Im
ete
lst
at
p21
Cleaved Caspase 3
Actin
UC
22
88
Ve
hic
le
UC
22
88
+Im
ete
lst
at
Im
ete
lst
at
p53
p21
*
*
*
Fig. 6. Simultaneous pharmacological inhibition of p21 by UC2288 and telomerase prevents tumor growth in mice. (A) Chemical structure of UC2288. (B)
Immunoblot of p21 expression in HCT116 cells treated with DMSO or with indicated concentrations of UC2288 for 24 h. (C) Relative cell viability measured by
trypan blue exclusion assay of HCT116 cells treated with imetelstat, UC2288 (2.5 μM), or both. (D) % Annexin V–FITC–positive HCT116 cells treated with
imetelstat and UC2288 was measured by FACS analysis. (E) Immunoblot for indicated proteins in HCT116 cells following treatment with U2288, imetelstat, or
both. (F) Relative cell viability measured by trypan blue exclusion assay of imetelstat-treated HCT116 cells transfected with control or p21 expression vectors
and then treated with UC2288. (G) % Annexin V–FITC–positive cells was measured by FACS analysis of imetelstat-treated HCT116 cells transfected with control
or p21 expression vectors and then treated with UC2288. (H) Cleaved caspase 3 was measured by immunoblot in imetelstat-treated HCT116 cells transfected
with control or p21 expression vectors and then treated with UC2288. (I) Average tumor volumes of HCT116 xenograft frommice treated with vehicle, UC2288
alone, imetelstat alone, or both drugs. **P < 0.001; ***P < 0.0001. (J) Average tumor volumes of ACHN xenograft from mice treated with vehicle, UC2288
alone, imetelstat alone, or both drugs. (K) Mouse-derived HCT116 xenograft tumors under indicated treatment conditions were analyzed for indicated
proteins by immunoblot analysis. (L) Mouse-derived ACHN xenograft tumors under indicated treatment conditions were analyzed for indicated proteins by
immunoblot analysis. *P < 0.01; **P < 0.001; ***P < 0.0001.
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into the flanks of athymic nude mice and followed it by treat-
ment with UC2288, imetelstat, or both drugs. Notably, combined
treatment with UC2288 and imetelstat synergistically suppressed
tumor growth (Fig. 6 I–L and SI Appendix, Table S2).
Toxicity analyses revealed that there were no significant dif-
ferences in the body weight or ALT, AST, AP, whole blood
counts, and renal activity markers in mice that were treated with
imetelstat, UC2288, or both drugs, in comparison with the con-
trol group (SI Appendix, Fig. S15).
Targeting Tumors Containing Mutant p53 Following Pharmacological
Restoration of p53 Activity. The results described above show that
in the absence of p21, p53 and E2F1 cooperate to activate PUMA
expression, which is necessary for apoptosis induction (Figs. 3 and
4). Accordingly, cells that lack functional p53 are less sensitive to
imetelstat-mediated growth inhibition compared with cells con-
taining wild-type p53 (Fig. 3J).
Approximately 50% of human cancers lack a functional p53
pathway, largely due to inactivating mutations in the p53 gene
(41). We therefore asked whether simultaneous inhibition of
telomerase and p21 could be adapted to treat cancers harboring
p53 mutants. Previous studies have shown that the function of
several different cancer-associated p53 mutants can be restored
by treatment with small molecules such as CP-31398 (42, 43).
CP-31398 alters the conformation of p53, thereby promoting its
ability to bind to DNA (42, 43). As expected, treatment of p53
mutant cancer cell lines DLD1 (Ser241Phe), SW480 (Arg273His
and Pro309Ser), and A375.S2 (Arg249Ser) with CP-31398 re-
stored p53 activity, as evidenced by increased expression of its
transcriptional target p21 (Fig. 7A). Next, using shRNAs, we
knocked down p21 in DLD1 and A375.S2 cells (Fig. 7B) and
treated these cells with imetelstat and CP-31398. Treatment with
both CP-31398 and imetelstat inhibited the growth of DLD1 and
A375 cells expressing a p21 shRNA more strongly compared with
A
p21
Actin
shRNA:
NS #1 #2 NS #1 #2
p21 p21
C D E
DLD1 A375.S2B
p21
Actin
DLD1 SW480 A375.S2
CP-31398 (µg/ml) 0       2      5         0       2       5         0       2       5
F
Imetelstat
CP-31398
-  +  -  +    -   +  -  +       -   +  -  +
-  -  +  + -   -  +  + -   -  +  +
shRNA: NS #1 #2
p21
0
20
40
60
80
100
C
el
l V
ia
bi
lit
y 
(%
)
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
0
10
20
30
40
50
60
70
80
0
20
40
60
80
100
120
G H
%
 A
nn
ex
in
 V
 p
os
iti
ve
 c
el
ls
R
el
at
iv
e 
P
U
M
A 
ex
pr
es
si
on
-  +  -  +    -   +  -  +       -   +  -  +
-  -  +  + -   -  +  + -   -  +  +
NS #1 #2
p21
-  +  -  +    -   +  -  +       -   +  -  +
-  -  +  + -   -  +  + -   -  +  +
NS #1 #2
p21
Imetelstat
CP-31398
-  +  -  +    -   +  -  +       -   +  -  +
-  -  +  + -   -  +  + -   -  +  +
shRNA: NS #1 #2
p21
0
20
40
60
80
100
C
el
l V
ia
bi
lit
y 
(%
)
-  +  -  +    -   +  -  +       -   +  -  +
-  -  +  + -   -  +  + -   -  +  +
NS #1 #2
p21
-  +  -  +    -   +  -  +       -   +  -  +
-  -  +  + -   -  +  + -   -  +  +
NS #1 #2
p21
R
el
at
iv
e 
P
U
M
A 
 e
xp
re
ss
io
n
%
 A
nn
ex
in
 V
 p
os
iti
ve
 c
el
ls
DLD1 DLD1 DLD1
A375.S2 A375.S2 A375.S2
I J
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Vehicle
CP-31398
Imetelstat
CP-31398
+ Imetelstat
0
100
200
300
400
500
600
700
800
0
200
400
600
800
1000
Vehicle
CP-31398
Imetelstat
CP-31398
+ Imetelstat
N
S
 s
iR
N
A
p2
1 
si
R
N
A
**
**
**
Days
7 14 21 28
Days
7 14 21 28
* * *
*
** **
*
** **
* * *
Fig. 7. Pharmacological restoration of p53 activity allows for the targeting of p53 mutant cancers by simultaneous p21 and telomerase inhibition. (A) In-
dicated p53 mutant cancer cell lines were treated at indicated concentrations of CP-31398 and analyzed for p21 expression by immunoblot. Actin was used as
a loading control. (B) Indicated p53 mutant cancer cell lines expressing either an NS shRNA or shRNA targeting p21 were analyzed for p21 expression by
immunoblot. Actin was used as a loading control. (C and F) DLD1 cells (C) or A375.S2 cells (F) expressing indicated shRNAs were treated with mismatch
oligonucleotide or imetelstat for 6 wk and were either untreated or treated with CP-31398 for 2 d. Cell viability was measured by trypan blue assay, and
relative cell viability is plotted. (D and G) DLD1 cells (D) or A375.S2 cells (G) expressing indicated shRNAs were treated with mismatch oligonucleotide or
imetelstat for 6 wk and were either untreated or treated with CP-31398 for 2 d. Apoptosis was measured by Annexin V staining, and % apoptosis is plotted.
(E and H) DLD1 cells (E) or A375.S2 cells (H) expressing indicated shRNAs were treated with mismatch oligonucleotide or imetelstat for 6 wk and were either
untreated or treated with CP-31398 for 2 d. PUMA expression was measured by qRT-PCR. (I and J) Average tumor volumes of DLD1 xenograft (I) or A375.S2 (J)
from mice treated with vehicle, CP-31398 alone, imetelstat alone, or both drugs with simultaneous treatment with nanoparticles with nonspecific or p21
siRNA are shown. *P < 0.01; **P < 0.001; ***P < 0.0001.
Gupta et al. PNAS | Published online July 14, 2014 | E3069
G
EN
ET
IC
S
PN
A
S
PL
U
S
cells expressing a nonspecific shRNA (Fig. 7 C and F and SI
Appendix, Fig. S16). Growth inhibition correlated with increased
apoptosis (Fig. 7 D and G) and significantly higher PUMA ac-
tivation (Fig. 7 E and H). Finally, we tested this approach for
suppressing tumor growth in vivo. We found that addition of CP-
31398 combined with simultaneous inhibition of telomerase and
p21 substantially suppressed growth of tumors containing mutant
p53 (Fig. 7 I and J). Collectively, these results show that simul-
taneous inhibition of telomerase and p21 can also be used to
treat cancers containing mutant p53.
Discussion
A large majority of diverse tumor types express telomerase, which
is critical for cancer cell survival. Thus, inhibition of telomerase
activity can block tumor cell growth both in vitro and in vivo. Due
to such widespread expression and the requirement of telomerase
for cancer cell survival, telomerase inhibitors can, in principle, be
used to treat a broad spectrum of cancer types. In fact, telomerase
inhibitors such as imetelstat have advanced into the clinic for the
treatment of human cancers. However, for several reasons, single-
agent telomerase therapies have not proven effective. First, because
telomere shortening and consequential tumor growth inhibition
require many cell divisions, single-agent telomerase inhibitors
require substantial time to significantly decrease tumor growth.
Second, telomerase inhibition typically results in only a cytostatic
effect, which allows tumor cells to acquire secondary genetic and
epigenetic alterations resulting in drug resistance. Finally, single-
agent telomerase therapeutics often fail due to activation of ALT
pathways, which bypasses the requirement for telomerase (25).
In this report, we have studied the role of p21 in telomerase
inhibition-mediated growth suppression. We found that p21 loss
increases apoptosis induction following telomerase inhibition in
a variety of cancer cell lines and mouse xenografts. We further
showed that apoptosis induction is specifically due to up-regulation
of PUMA expression and that up-regulation of PUMA expression
is dependent upon both p53 and E2F1. Although our results are
consistent with other studies reporting that p21 can regulate ap-
optosis (9–13), the specific apoptotic mechanism we identify has
not been previously described.
Previous studies have shown that p21 loss sensitizes cells to
DNA-damage–induced apoptosis (9–13). In our experiments,
treatment of cells with imetelstat induces a DNA damage re-
sponse, which upon simultaneous loss of p21, results in apo-
ptosis. Thus, the loss of p21 effectively converts the response of
imetelstat from simple growth inhibition to apoptosis. According
to this mechanism, the specificity of growth inhibition is due to
imetelstat, which will selectively induce a DNA damage response
in telomerase-positive cancer cells but not telomerase-negative
normal cells.
Our finding that p21 is required to prevent apoptosis following
telomerase inhibition reveals a critical genetic vulnerability of
telomerase-expressing cancer cells. Accordingly, using both RNAi-
based and pharmacological approaches, we showed that simulta-
neous inhibition of p21 and telomerase induces apoptosis in
telomerase-positive human cancer cell lines and synergistically
suppresses tumor growth. Specifically, we found that two unrelated
pharmacological inhibitors of p21, sorafenib and UC2288, could
function synergistically with imetelstat. Notably, in both cases,
growth inhibition could be counteracted by ectopic expression of
p21, indicating that sorafenib and UC2288 functioned by inhibiting
p21 and not through an off-target effect. The induction of apo-
ptosis by simultaneous inhibition of p21 and telomerase may
greatly reduce the likelihood that resistance to telomerase
inhibitors will develop through additional secondary genetic
alterations or activation of ALT pathways. Finally, we show that
simultaneous inhibition of telomerase and p21 also suppresses
growth of tumors containing mutant p53 following pharmaco-
logical restoration of p53 activity.
Overall, we anticipate that simultaneous inhibition of telo-
merase and p21 can potentially overcome the current limitation
of single-agent telomerase therapeutics and provide an effective
method to treat a large number of cancers that rely on telo-
merase activity for survival, including the p53 mutant cancers.
Materials and Methods
Materials and procedures for all experiments are supplied in SI Appendix.
Included in SI Appendix are the mammalian cell culture procedures, details
regarding tumorigenesis assay, protocols for TRAP assay to measure telo-
merase activity, Terminal Restriction Fragment analysis to measure telomere
length, and ALT activity assay to monitor C-Circle amplification. Also pro-
vided are additional figures and tables providing p16 status of the cell lines
used in our study, primer sequence information and antibody details used
for immunolotting, and the statistical analyses of drug combinations to es-
tablish synergistic effects.
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Supporting Information 
Materials and Methods 
Cell culture  
HCT116, p53KO, p21KO, and p21/PUMA DKO cells were a kind gift of Bert Vogelstein (Johns 
Hopkins Medical School). RKO, ACHN, LOX IMVI, UACC62, CAKI, NCI H460, DLD1, 
SW480, A375.S2 and U2OS cells were obtained from National Cancer Institute as part of the 
NCI 60 panel of cancer cell lines and from American Type Culture Collection (ATCC). The p21 
expression vector was a kind gift of William G. Kaelin (Dana Farber Cancer Institute). Cell lines 
were grown as recommended. TERT shRNAs were a kind gift of William Hahn (Harvard 
University). Lentiviral shRNA expression vectors were obtained from OpenBiosystems and were 
packaged by co-transfecting with lentiviral packaging plasmids into 293T cells using Effectene 
(Qiagen). After infection with lentivirus shRNA particles, cells stably transduced with lentiviral 
DNA were selected in medium containing puromycin. Cells were treated with 2.5 µM imetelstat 
or mismatch oligonucleotides (Geron Corporation) twice per week for up to 6 weeks and did not 
exceed 80% confluence during the treatment. Cells were treated with indicated concentrations of 
UC2288 at 80% confluence during the treatment. Cells were treated with indicated 
concentrations of CP-31398 at 80% confluence during the treatment. 
 
Cell viability and colony formation assay  
For viability assays, cells were mixed with an equal volume of Trypan Blue Solution 
(Invitrogen) and counted using Countess (Invitrogen). For colony formation assays, 103 cells 
were seeded in triplicate. Colonies were stained with 0.005% crystal-violet solution and counted 
after 10 days.   
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Nanoparticle Synthesis 
PLGA nanoparticles loaded with siRNA were fabricated using a double emulsion solvent 
evaporation method and coated with ANTP as previously described (37). After washing 
unencapsulated siRNA and unattached ANTP, nanoparticles were lyophilized with the 
cryoprotectant, trehalose, at an equal mass ratio of polymer to carbohydrate.  
 
Tumorigenesis assays  
Eight-week old, athymic nude (NCr nu/nu) mice (n=5) were injected subcutaneously with cancer 
cells (2.5x106). After one week, tumor-bearing mice received mismatch oligonucleotide or 
imetelstat (30 mg/kg bodyweight) three times per week by intraperitoneal injection. Sorafenib 
was dissolved in Cremophor EL/95% ethanol (50:50) (Sigma) as a 4X stock solution and diluted 
with sterile water before use. Sorafenib (15 mg/kg) was administered by oral gavage three times 
per week. UC2888 was dissolved in Oleic acid with PEG400 as a 4X stock solution. UC2288 
(15mg/kg body weight) was administered by oral gavage three times per week. For experiments 
using nanoparticles mice were injected with p21 or non-specific siRNA (1.0 mg/Kg body) two 
times a week. CP-31398 was administered at the concentration of 25 mg/kg everyday. Tumor 
growth was measured using calipers, and tumor volumes were calculated using the formula 0.5 X 
length X width2. TUNEL assays were performed as described previously (1). For body weight 
measurements, mice were weighed at the end of the experiments before sacrifice. Blood was 
collected from the tail vein for alkaline aminotransferase (ALT), aspratate aminotransferase 
(AST) and alkaline phosophatase (AP) activity analysis. ALT, AST and AP activities were 
measured using kits from Sigma-Aldrich. For complete blood analyses we did the following 
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experiments: Hematocrit (Packed red cell volume) was analyzed and calculated as percentage of 
packed cell volume to the total volume. For RBC count 10 µl whole blood was diluted 1:1000 
with PBS and RBC were counted using hemocytometer. For white blood cell count, we mixed 10 
µl whole blood with RBC lysis reagent and after 1 minute of incubation the white cells were 
counted by hemocytometer. For measuring kidney function and as an indicator of glomerular 
filtration rate Serum creatinine levels were measured using Creatinine assay kit as per the 
manufacturers recommendations (Abcam). 
 
Quantitative RT-PCR analysis 
Total RNA was extracted with TRIzol (Invitrogen) and purified using RNAeasy mini columns 
(Qiagen). First-strand cDNA was generated using ProtoScript M-MuLV First-Strand cDNA 
Synthesis Kit (New England Biolabs), and quantitative PCR was performed using Power SYBR 
Green PCR Master Mix (Applied Biosystems). p21, PUMA, BAX, BAK, TERT, MDC1, NBS1 
CDKN1B (p27) and E2F1 expression were analyzed using primers listed in Table S3. Actin 
mRNA was measured as an internal control. 
 
Immunoblot analysis  
Cell lysates were prepared using Pierce IP Lysis Buffer (Thermo Scientific) containing Protease 
Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO). 
Protein concentration was estimated using a Bradford Protein Assay kit (Bio-Rad Laboratories). 
Proteins were separated on 10% or 12% polyacrylamide gels and transferred to PVDF 
membranes using a Bio-Rad Trans-Blot wet transfer apparatus. Membranes were blocked with 
5% nonfat milk and probed with primary antibodies followed by the appropriate secondary HRP-
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conjugated antibody (GE healthcare, UK). Blots were developed using the SuperSignal West 
Pico Chemiluminescent Substrate (Pierce). Antibody information is provided in Table S3. 
 
FACS and Annexin V-FITC staining 
FACS analyses for sub G1 cell population were done as described previously (2). Briefly cells 
were fixed with 70% ethanol for overnight. The following day, cells were washed twice with 1X 
PBS and resuspended in 300 µl of 1X PBS, treated with RNAase (Sigma-Aldrich) and 
Propidium iodide for 1 hr and analyzed using FACSCaliber (BD Biosciences). Annexin V-
FITC/PE staining were performed as described previously (3) using a kit available from BD 
Bioscience, stained cells were analyzed using FACSCaliber (BD Biosciences).  
 
TRAP assay 
The TRAP assay was performed essentially as described (4). Briefly, cells were washed once 
with ice cold PBS, resuspended in 100µL of ice-cold CHAPS lysis buffer (10 mM Tris-HCl (pH 
7.5), 1 mM MgCl2, 1 mM EGTA, 0.5% CHAPS, 10% glycerol and 5 mM beta-mercaptoethanol) 
and incubated 25 min on ice to lyse. Lysates were centrifuged for 20 min at 13,000 rpm at 4°C, 
supernatants were collected, and protein concentrations were measured using a Bradford Protein 
Assay Kit (Bio-Rad Laboratories). For the preparation of lysates equal weight tumor tissue was 
homogenized and processed similar to as described above. Telomerase activity was measured 
using a SYBR Green RQ-TRAP assay with 750 ng lysate, 0.1 µg telomerase primer TS and 0.05 
µg anchored return primer ACX in a 25 µl reaction volume with SYBR Green PCR Master Mix 
(Applied Biosystems). TS and ACX primer sequences are provided in Table S3. Samples were 
analyzed using a CFX96 thermal cycler (Bio-Rad laboratories) by incubating for 20 minutes at 
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25°C, and amplified in a 35 cycle, two-step PCR with the conditions: 30 seconds at 95°C, and 90 
seconds at 60°C. The threshold cycle values (Ct) were determined from semi-log amplification 
plots (log increase in fluorescence versus cycle number). Every plate included standards, 
inactivated samples and lysis buffer as controls. Each sample was analyzed at least in triplicate. 
Telomerase activity was plotted relative to untreated cells.  
 
Telomere PNA FISH analysis 
Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) was performed as 
described (5). Briefly, cells were treated with 0.5 µg/ml of colcemid for 3.5 hrs to arrest cells in 
metaphase.  Trypsinized cells were incubated in 0.6 M KCl, fixed with methanol:acetic acid 
(3:1) and spread on glass slides. Metaphase chromosome spreads were hybridized with the 
telomeric PNA probe, 5ʹ′-Tam-OO-(CCCTAA)4-3ʹ′. Chromosome images and telomere signals 
were captured and processed using a Nikon Eclipse 80i microscope and NIS-elements BR 3.1 
software. At least 1000 chromosomes per sample were scored for telomere loss (i.e., signal free 
ends). 
 
Terminal Restriction Fragment (TRF) analysis 
Terminal Restriction Fragment (TRF) southern blot analysis was performed as described (6). 
Briefly, cells were trypsinized and embedded in 1% agarose plugs (2x106 cells per plug). Plugs 
were incubated in proteinase K digestion buffer (500 mM EDTA pH 8.0, 2% N- laurylsarcosine, 
and 20 mg/ml proteinase K) at 56ºC overnight. Plugs were washed with TE buffer for several hrs 
and then digested with RsaI and HinfI endonucleases at 37°C overnight. Plugs were loaded into 
1% agarose gels for pulsed-field gel electrophoresis. After electrophoresis, gels were dried, and 
soaked in denaturing solution (0.2 N NaOH, 0.6 M NaCl) for 1 hr to denature DNA, followed by 
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neutralizing solution (1.5M NaCl, 0.5M Tris-Cl pH 7.4) for 1 hr. To detect telomere fragments, 
in-gel hybridization was performed using γ-32P-(CCCTAAA)4 oligonucleotide probe, gels were 
washed and exposed to a PhosphorImager screen. Telomere hybridization signals were scanned 
using a Typhoon PhosphorImager and quantified using ImageQuant software (GE).  
 
ALT activity assay by monitoring C-Circle amplification 
Rolling Circle Amplification (RCA) of C-circle DNA was performed as described (26), using 
2x105 cells per sample. The RCA reaction was carried out in 20µl reaction using 200 ng of DNA 
and from each samples (1/10th) of the reaction was spotted to a Biodyne B membrane (Pall 
Corporation). Membranes were UV irradiated to crosslink DNA and pre-hybridized using 
PerfectHyb Plus hybridization buffer (Sigma-Aldrich) at 37°C for 1 hr. Membranes were 
hybridized with a γ-32P-labelled (CCCTAA)3 probe. The hybridized membrane was 
autoradiographed at -80°C for 1 day and developed to detect C-circle amplification products.   
 
Statistical Analysis 
All the experiments were performed at least three times in triplicates, and the data are expressed 
as Mean ± Standard Error Mean (SEM).  Area Under the Curve (AUC) values were calculated 
using GraphPad Prism version 6.02 for Machintosh, GraphPad Software, San Diego California 
USA (www.graphpad.com).  Student’s t-test for two-tailed distribution with unequal variance 
was performed in Microsoft Excel to derive the p-values. 
For synergy analyses, we used R, a system for statistical computation and graphics (49), 
we assessed whether the combined effects from two drugs were additive (responses were equal 
to the sum of the single-drug effects), synergistic (greater than the sum of the single-drug effects) 
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or antagonistic (less than the sum of the single-drug effects) on tumor growth in a given cancer 
cell lines. Two-way analysis of variance (ANOVA) was used to test for the main effects of the 
drugs and their interaction on tumor size at the end point data for each all cell lines. Bonferroni 
correction was performed to counteract the problem of multiple comparisons (7). To determine 
whether various drug combinations exerted additive, synergistic or antagonistic impacts on 
decreasing tumor size, we compared the difference between observed effects with the expected 
additive effects for the mouse treated with both drugs (7). The difference was estimated as the 
interaction coefficient in the ANOVA. If there is a significant positive difference (i.e., interaction 
coefficient > 0 and Bonferroni adjusted p-value < 0.01), then the impact from the combined 
drugs was classified as antagonism. If there is a significant negative difference (i.e., interaction 
coefficient  < 0  and  Bonferroni  adjusted p-value < 0.01), then the impact from the combined 
drugs was classified as synergistic on decreasing tumor size. If there is no significant difference, 
then the impact from the combined drugs was classified as additive. 
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Table S1. p16 status of the telomerase positive cancer cell lines used in this study. 
 
Cell line  Alteration in p16 
ACHN Homozygous deletion 
CAKI Homozygous deletion 
HCT116 Point mutation (Premature termination codon 80 (CGA-TGA) 
LOX IMVI Homozygous deletion 
NCI H460 Homozygous deletion 
OVCAR5 Homozygous deletion 
RKO DNA hypermethylation of the p16 promoter 
UACC62 Homozygous deletion 
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 Table S2. Results of statistical analyses to determine synergism, antagonism and additive effects 
among indicated siRNA and drug combinations. 
 
Cell line Effect Coefficient p-Value Synergism/Antago
nism/Additive 
Bonferroni Adjusted 
p-value 
Nanoparticle encapsulated p21 
siRNA main effect 
103.4 .00144248  1.88E-02 
Imetelstat main effect -118.6 9.4-E-08  1.22E-06 
HCT116 
p21 siRNA: Imetelstat interaction -528.4 1.04E-05 Synergism 1.35E-04 
Nanoparticle encapsulated p21 
siRNA main effect 
44 3.75E-22  4.88E-21 
Imetelstat main effect -89 4.94E-26  6.24E-25 
ACHN 
p21 siRNA: Imetelstat interaction -443 1.09E-23 Synergism 1.42E-22 
Sorafenib main effect -182 2.43E-22  3.159E-21 
Imetelstat main effect -241 5.30E-24  6.89E-23 
HCT116 
Sorafenib: Imetelstat interaction -72 4.23E-10 Synergism 5.499E-20 
Sorafenib main effect -173 1.34E-33  1.742E-21 
Imetelstat main effect -131 2.78E-21  3.614E-20 
RKO 
Sorafenib: Imetelstat interaction -139 5.35E-14 Synergism 6.955E-13 
Sorafenib main effect -120 8.49E-20  1.1037E-18 
Imetelstat main effect -70 5.71E-18  7.423E-17 
ACHN 
Sorafenib: Imetelstat interaction -190 3.44E-14 Synergism 4.472E-13 
Sorafenib main effect -80 2.17E-20  2.82E-19 
Imetelstat main effect -202 9.92E-24  1.29E-22 
LOXIMVI 
Sorafenib: Imetelstat interaction -234 8.54E-17 Synergism 1.11E-15 
Sorafenib main effect -42 4.98E-19  6.47E-18 
Imetelstat main effect -294 4.06E-25  5.28E-24 
UACC62 
Sorafenib: Imetelstat interaction -274 3.47E-17 Synergism 4.51E-16 
Sorafenib main effect -30 2.70E-20  3.15E-19 
Imetelstat main effect -205 3.74E-25  4.86E-24 
CAKI 
Sorafenib: Imetelstat interaction -265 1.12E-18 Synergism 1.46E-17 
UC2288 main effect -90 1.18E-19  1.53E-18 
Imetelstat main effect -295 3.57E-24  4.641E-23 
HCT116 
UC2288: Imetelstat interaction -266 4.27E-16 Synergism 5.55E-15 
UC2288 main effect -18 1.01E-19  1.313E-18 
Imetelstat main effect -128 7.56E-23  9.828E-22 
ACHN 
UC2288:Imetelstat interaction -350 4.78E-19 Synergism 6.214E-18 
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Table S3. Primer sequences for RT-qPCR analysis; clone ID and catalog numbers for 
shRNAs (Open Biosystems); antibodies used; source and concentration of chemical 
inhibitors used. 
 
Application  Gene symbol Forward primer (5ʹ′-3ʹ′) Reverse primer (5ʹ′-3ʹ′) 
RT-qPCR CDKN1A (p21) GCAGACCAGCATGACAGATTT GGATTAGGGCTTCCTCTTGGA 
 PUMA TCGGTGCTCCTTCACTCTGG GCAAACGAGCCCCACTCTCT 
 BAX ACCAAGGTGCCGGAACTGAT ACTCCCGCCACAAAGATGGT 
 BAK GCCCAGGACACAGAGGAGGT CCATGGTGCTGCTAGGTTGC 
 ACTIN GCATGGAGTCCTGTGGCATC TTCTGCATCCTGTCGGCAAT 
 E2F1 TCCCTCCTGCAGTGTCTGAA CAGCGAGGAAGCTGACCTTT 
 MDC1 GCCTTTTGACACGCACCTTG GCCCACCCTCTCTGCTGTTT 
 NBS1 TGTCAGGACGGCAGGAAAGA TTCCCGGAGCAAAAAGAAA 
 CDKN1B (p27) GCTCCGGCTAACTCTGAGGA AAGAATCGTCGGTTGCAGGT 
 TERT GACACACATTCCACAGGTCG GACTCGACACCGTGTCACCTAC 
 ACX GCGCGGCTTACCCTTACCCTTACCCTAACC  
 TS AATCCGTCGAGCAGAGTT  
 RCA CCCTAACCCTAACCCTAA  
 
 Gene symbol Clone ID Catalog number 
shRNAs CDKN1A (p21) TRCN0000040123 RHS3979-9607512 
  TRCN0000040125 RHS3979-9607514 
 MDC1 TRCN0000018850 RHS3979-9586172 
  TRCN0000018851 RHS3979-9586173 
 NBS1 TRCN0000040137 RHS3979-9607526 
  TRCN0000010393 RHS3979-9630894 
 E2F1 TRCN0000000251 RHS3979-9568611 
  TRCN0000000253 RHS3979-9568613 
 PUMA  
TRCN0000033611 
 
RHS3979-9601019 
 
 CDKN1B TRCN0000039929  RHS3979-9607318 
  TRCN0000009856  RHS3979-97079654 
siRNA Gene symbol  Sequence 
 CDKN1A (p21) Thermoscientific GCGAUGGAACUUCGACUUU 
 Non-targeting Thermoscientific UAAGGCUAUGAAGAGAUAC 
 
 Protein symbol Antibody source  
Immunoblot/ CDKN1A (p21) Santa Cruz Biotechnology, Inc.  
ChIP PUMA Thermo Scientific  
 BAX Santa Cruz Biotechnology, Inc.  
 BAK Santa Cruz Biotechnology, Inc.  
 TERT R & D Systems  
 p53 Santa Cruz Biotechnology, Inc.  
 Cleaved caspase 3 Cell signaling  
 Actin Sigma-Aldrich  
 
 Inhibitor Concentration Source 
 Imetelstat 2.5 µM Geron Corporation 
 Mismatch Oligonucleotide 2.5 µM Geron Corporation 
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 Sorafenib 1 µM and 2.5 µM LC Laboratories 
 UC2288 1 µM, 2.5 µM and 5 µM  
 CP-31398 2 and 5 µg/ml Sigma-Aldrich 
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Supplementary figure legends 
Fig. S1. shRNA-mediated inhibition of TERT expression leads to potent growth inhibition 
in HCT116 p21KO cells. Analysis of HCT116 p21KO (A–D) or wild-type (E–H) cells stably 
transduced with non-specific control (NS) or two different TERT shRNAs. (A, E) qRT-PCR 
analysis of TERT mRNA. (B, F) Cell viability as measured by trypan blue exclusion assay. Cell 
viability relative to non-specific shRNA is plotted. (C, G) Annexin V-FITC positive cells were 
quantified by FACS analysis. % Annexin V-FITC positive cells are plotted. (D, H) Telomerase 
activity as measured by the TRAP assay and plotted relative to the mismatch oligonucleotide. 
*** represents p<0.0001. 
 
Fig. S2. shRNA-mediated loss of p21 leads to apoptosis induction upon telomerase 
inhibition. Analysis of HCT116 cells stably transduced with non-specific control (NS) or two 
different p21 shRNAs. (A) Immunoblot analysis of p21 protein. (B) qRT-PCR analysis of p21 
mRNA. (C-F) Cells were treated with mismatch oligonucleotide or with imetelstat for 6 weeks. 
(C) Colony formation monitored by crystal violet staining. (D) Cell viability as measured by 
trypan blue exclusion assay. Cell viability relative to mismatch oligonucleotide is plotted. (E) 
Apoptosis monitored by FACS analysis. (F) Annexin V-FITC positive cells were quantified 
using FACS analysis. % Annexin V-FITC positive cells are plotted. (G) Telomerase activity as 
measured by the TRAP assay and plotted relative to the mismatch oligonucleotide. ** and *** 
represents p<0.001 and p<0.0001 respectively. 
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Fig. S3.  shRNA-mediated p21 knockdown in unrelated human cancer cell lines sensitize 
them to telomerase inhibition-mediated apoptosis. (A, B) Immunoblot analysis of RKO (A) 
and ACHN (B) cells stably transduced with non-specific control (NS) or two different p21 
shRNAs. (C) (Left) p21 gene specific probes intensity values for the indicated cell lines were 
obtained from BioGPS, Relative p21 expression is plotted. (Right) Immunoblot analysis to 
monitor p21 expression levels in the indicated cell lines. Actin was used as a loading control. (D-
F) Indicated cells were treated with mismatch oligonucleotide or with imetelstat for 6 weeks. (D) 
Cell viability was measured by trypan blue exclusion assay. Cell viability relative to mismatch 
oligonucleotide is plotted. (E) Annexin V-FITC positive cells were quantified for indicated cell 
lines using FACS analyses. % Annexin V positive cells under indicated conditions is plotted. (F) 
Telomerase activity as measured by the TRAP assay and plotted relative to the mismatch 
oligonucleotide. (G) Dot blot analysis of rolling circle amplification of C-circle DNA to measure 
ALT activity in the indicated cell lines. ** and *** represents p<0.001 and p<0.0001 
respectively.  
 
Fig. S4.  Loss of checkpoint proteins MDC1 or NBS1 do not cooperate with telomerase 
inhibition to induce growth arrest. HCT116 cells stably transduced with MDC1 (A–F) or NBS1 
(G–L) shRNAs. Where indicated, cells were treated either with mismatch oligonucleotide or 
imetelstat for 6 weeks. (A, G) qRT-PCR analysis of MDC1 (A) or NBS1 (G) mRNA. (B, H) 
Colony formation monitored by crystal violet staining. (C, I) Cell viability as measured by trypan 
blue exclusion assay. Cell viability relative to mismatch oligonucleotide is plotted. (D, J) 
Apoptosis monitored by FACS analysis. (E, K) Telomerase activity as measured by the TRAP 
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assay and plotted relative to the mismatch oligonucleotide. (F, L) qRT-PCR analysis of PUMA 
mRNA.  *** represents p<0.0001.   
 
Fig. S5.  Loss of cyclin dependent kinase inhibitor p27 does not cooperate with telomerase 
inhibition to induce growth arrest. HCT116 cells stably transduced with p27 shRNAs and 
where indicated, cells were treated either with mismatch oligonucleotide or imetelstat for 6 
weeks. (A) qRT-PCR analysis of p27 mRNA. (B) Colony formation monitored by crystal violet 
staining. (C) Cell viability as measured by trypan blue exclusion assay. Cell viability relative to 
mismatch oligonucleotide is plotted. (D) Apoptosis monitored by FACS analysis of sub G1 
population. (E) Telomerase activity as measured by the TRAP assay and plotted relative to the 
mismatch oligonucleotide. (F) qRT-PCR analysis of PUMA mRNA. 
 
Fig. S6. ER-stress inducer tunicamycin does not enhance tumor cell growth after Imetelstat 
treatment or loss of p21. (A) Relative cell viability measured by trypan blue exclusion assay of 
HCT116 cells that were either remained untreated or treated with imetelstat, tunicamycin or 
both.  (B) Apoptosis was measured by Annexin V-FITC staining for HCT116 cells that were 
either remained untreated or treated with imetelstat, tunicamycin or both.  (C) Relative cell 
viability measured by trypan blue exclusion assay of HCT116 wild type or p21 KO cells that 
were either remained untreated or treated with tunicamycin. (D) Apoptosis was measured by 
Annexin V-FITC staining for HCT116 wild type or p21 KO cells that were either remained 
untreated or treated with tunicamycin.  
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Fig. S7. p21 does not regulate the ability of imetelstat to inhibit telomerase activity, 
telomere shortening or ALT. Indicated cell lines were treated with mismatch oligonucleotide or 
imetelstat for 6 weeks. (A) Southern blot to measure telomere length. Size markers in kilobase 
are shown next to the gel image. (B) Telomere length relative to HCT116 cells treated with 
mismatch oligonucleotide, in all indicated cell lines corresponding to (A) is presented. (C) 
Telomere PNA-FISH to monitor signal-free chromosomal ends. (D) Signal-free chromosomal 
ends in (C) were quantified and plotted relative to mismatch oligonucleotide. (E) Dot blot 
analysis of rolling circle amplification of C-circle DNA to measure ALT activity in the indicated 
cell lines. ** represents p<0.001. 
 
Fig. S8.  Treatment of ALT activated cell line U2OS with imetelstat did not induce growth 
inhibition irrespective of p21 expression. (A, B) U2OS cells expressing indicated shRNAs 
were treated with either a mismatch oligonucleotide or with Imetelstat for 6 weeks. (A) Colony 
formation was monitored by crystal violet staining. (B) cell viability was measured by trypan 
blue exclusion assay  
 
Fig. S9.  PUMA activation is a general requirement for telomerase inhibition-induced 
tumor suppression. (A, B) RKO cells with indicated shRNAs were treated with either a 
mismatch oligonucleotide or imetelstat for 6 weeks. (A) Fold change in PUMA transcript levels 
measured by qRT-PCR (B) Immunoblot analysis was performed for indicated proteins. (C) 
PUMA knockdown in p21 shRNA expressing RKO cells was confirmed by qRT-PCR. (D-F) 
RKO cells with indicated shRNAs were treated with either a mismatch oligonucleotide or 
imetelstat for 6 weeks. (D) Relative cell viability was measured by trypan blue exclusion assay. 
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(E) Annexin V-FITC positive cells were quantified using FACS analysis. % Annexin V-FITC 
positive cells are plotted. (F) Relative telomerase activities of indicated cells. (G, H) ACHN cells 
with indicated shRNAs were treated with either a mismatch oligonucleotide or imetelstat for 6 
weeks. (G) Fold change in PUMA transcript levels measured by qRT-PCR. (H) Immunoblot 
analysis was performed for indicated proteins. (I) PUMA knockdown in p21 shRNA expressing 
ACHN cells was confirmed by qRT-PCR. (J-L) ACHN cells with indicated shRNAs were treated 
with either a mismatch oligonucleotide or imetelstat for 6 weeks. (J) Cell viability was measured 
by trypan blue exclusion assay. (K) Annexin V-FITC positive cells were quantified using FACS 
analysis. % Annexin V-FITC positive cells are plotted. (L) Relative telomerase activities of 
indicated cells. ** represents p<0.001. 
 
Fig. S10.  Analyses of telomerase activity by TRAP assay. (A) Relative telomerase activities 
of HCT116 p21KO cells expressing indicated shRNAs and treated with a mismatch 
oligonucleotide (-) or with imetelstat (+). (B) Relative telomerase activities of HCT116 wild type 
and p53KO cells treated with a mismatch oligonucleotide (-) or with imetelstat (+).  
 
Fig. S11. Telomerase inhibition-induces strong tumor suppression in cancer cells with 
lower p21 expression in a PUMA dependent manner. (A) Indicated cell lines were treated with 
either a mismatch oligonucleotide or imetelstat for 6 weeks. Fold change in PUMA transcript 
levels measured by qRT-PCR. (B) PUMA knockdown in NCI H460 and OVCAR5 cells was 
confirmed by qRT-PCR. (C, D) Indicated cell lines were treated with either a mismatch 
oligonucleotide or imetelstat. (C) Cell viability was measured by trypan blue exclusion assay. 
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(D) Relative telomerase activities of indicated cells. * and ** represents p<0.01 and p<0.001 
respectively. 
 
Fig. S12.  Nanoparticle-based systemic p21 siRNA delivery inhibits the growth of tumors in 
combination with imetelstat treatment. (A) HCT116 cells were injected into the flanks of nude 
mice and were treated as indicated. Tumor volumes at indicated days are shown and the 
representative tumors are presented. (B) ACHN cells were injected into the flanks of nude mice 
and were treated as indicated. Tumor volumes at indicated days are shown and the representative 
tumors are presented. (C) Mouse derived HCT116 xenograft tumor under indicated treatment 
conditions were analyzed for indicated proteins by immunoblot analysis. (D) Mouse derived 
ACHN xenograft tumor under indicated treatment conditions were analyzed for indicated 
proteins by immunoblot analysis. (E) Mouse derived HCT116 xenograft tumor under indicated 
treatment conditions were analyzed for telomerase activity by TRAP assay. (F) Mouse derived 
ACHN xenograft tumor under indicated treatment conditions were analyzed for telomerase 
activity by TRAP assay. * , **, *** represents p<0.01, p<0.001, p<0.0001  respectively 
 
Fig. S13.  Analyses of the drug toxicity of sorafinib, imetelstat and their combination in 
mice.  (A) Control mice group bearing HCT116 tumors or HCT116 tumor bearing mice treated 
with the indicated drugs were weighed at the end of the experiment. Average reduction in body 
weight in drug treatment group is plotted in comparison to control mice. (B) Activities of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) were 
analyzed in the sera of the indicated mice groups. Activities of these enzymes in comparison to 
the control mice group is plotted. (C) Relative hemacrite (packed red cell volume) level in 
 19 
HCT116 tumor bearing mice, compared to vehicle control. (D) Relative Red Blood cell (RBC) 
count in HCT116 tumor bearing mice under indicated condition, compared to vehicle control. 
(E) Relative White blood cell (WBC) count in HCT116 tumor bearing mice under indicated 
condition, compared to vehicle control. (F) Activity of creatinine in the sera of the indicated 
mice groups. Activities in comparison to the control mice group is plotted. 
Fig. S14. Simultaneous inhibition of telomerase and p21 cause synergistic tumor 
suppression in a wide variety of cancer cells. (A-E) Average tumor volumes from mice treated 
with vehicle, sorafenib alone, imetelstat alone or with both drugs for indicated cell lines. *** 
represents p<0.0001. 
 
Fig. S15.  Analyses of the drug toxicity of UC2288, imetelstat and their combination in 
mice.  (A) Control mice group bearing HCT116 tumors or HCT116 tumor bearing mice treated 
with the indicated drugs were weighed at the end of the experiment. Average reduction in body 
weight in drug treatment group is plotted in comparison to control mice. (B) Activities of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) were 
analyzed in the sera of the indicated mice groups. Activities of these enzymes in comparison to 
the control mice group is plotted. (C) Relative hemacrite (packed red cell volume) level in 
HCT116 tumor bearing mice, compared to vehicle control. (D) Relative Red Blood cell (RBC) 
count in HCT116 tumor bearing mice under indicated condition, compared to vehicle control. 
(E) Relative White blood cell (WBC) count in HCT116 tumor bearing mice under indicated 
condition, compared to vehicle control. (F) Activity of creatinine in the sera of the indicated 
mice groups. Activities in comparison to the control mice group, is plotted. 
 
 20 
Fig. S16. Telomerase activity measurement.  DLD1 (Left) and A375.S2 (Right) cells treated 
as indicated were analyzed for telomerase activity. Relative telomerase activity is plotted. 
 21 
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